Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA

References

• Interno V, De Santis P, Stucci LS, Ruda R, Tucci M, Soffietti R, Porta C. Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: an overview. Cancers (Basel). 2021;13(9):2114. doi:10.3390/cancers13092114
   PubMed Web of Science ®Google Scholar
• Bianchi, M, Sun, M, Jeldres, C, Shariat, S F, Trinh, Q-D, Briganti, A, Tian, Z, Schmitges, J, Graefen, M, Perrotte, P, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–980. doi:10.1093/annonc/mdr362
   PubMed Web of Science ®Google Scholar
• Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4): 245–261. doi:10.1038/s41581-020-00359-2
   PubMed Web of Science ®Google Scholar
• Larroquette M, Peyraud F, Domblides C, Lefort F, Bernhard J-C, Ravaud A, Gross-Goupil M. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives. Cancer Treat Rev. 2021;97:102207. doi:10.1016/j.ctrv.2021.102207
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang Z, Fan Y, Zhang Q. Epigenetic alterations in renal cell cancer with TKIs resistance: from mechanisms to clinical applications. Front Genet. 2020;11:562868,. doi:10.3389/fgene.2020.562868
   PubMed Web of Science ®Google Scholar
• Hayashi K, Narutaki K, Nagaoka Y, Hayashi T, Uesato S. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull. 2010;33(7):1199–1205. doi:10.1248/bpb.33.1199
   PubMed Web of Science ®Google Scholar
• Kang HS, Lee JY, Kim CJ. Anti-inflammatory activity of arctigenin from Forsythiae Fructus. J Ethnopharmacol. 2008;116(2):305–312. doi:10.1016/j.jep.2007.11.030
   PubMed Web of Science ®Google Scholar
• Shi H, Zhao L, Guo X, Fang R, Zhang H, Dong G, Fu J, Yan F, Zhang J, Ning J, et al. Arctigenin attenuates breast cancer progression through decreasing GM-CSF/TSLP/STAT3/beta-catenin signaling. Int J Mol Sci. 2020;21(17):6357. doi:10.3390/ijms21176357
   PubMed Web of Science ®Google Scholar
• Jeong JB, Hong SC, Jeong HJ, Koo JS. Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells. Int Immunopharmacol. 2011;11(10):1573–1577. doi:10.1016/j.intimp.2011.05.016
   PubMed Web of Science ®Google Scholar
• Wang HQ, Jin JJ, Wang J. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression. J Biochem Mol Toxicol. 2014;28(1):39–45. doi:10.1002/jbt.21533
   PubMed Web of Science ®Google Scholar
• Yao X, Zhu F, Zhao Z, Liu C, Luo L, Yin Z. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. J Cell Biochem. 2011;112(10):2837–2849. doi:10.1002/jcb.23198
   PubMed Web of Science ®Google Scholar
• Wang Y, Lina L, Xu L, Yang Z, Qian Z, Zhou J, Suoni L. Arctigenin enhances the sensitivity of cisplatin resistant colorectal cancer cell by activating autophagy. Biochem Biophys Res Commun. 2019;520(1):20–26. doi:10.1016/j.bbrc.2019.09.086
   PubMed Web of Science ®Google Scholar
• Maxwell T, Lee KS, Kim S, Nam KS. Arctigenin inhibits the activation of the mTOR pathway, resulting in autophagic cell death and decreased ER expression in ER-positive human breast cancer cells. Int J Oncol. 2018;52(4):1339–1349. doi:10.3892/ijo.2018.4271
   PubMed Web of Science ®Google Scholar
• Liu D, Zhou G, Shi H, Chen B, Sun X, Zhang X. Downregulation of transmembrane protein 40 by miR-138-5p suppresses cell proliferation and mobility in clear cell renal cell carcinoma. Iran J Biotechnol. 2020;18(1):e2270. doi:10.30498/IJB.2019.85193
   PubMed Web of Science ®Google Scholar
• Kohn AD, Takeuchi F, Roth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem. 1996;271(36):21920–21926. 10.1074/jbc.271.36.21920
   PubMed Web of Science ®Google Scholar
• Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016;15(1):83. doi:10.1186/s12943-016-0565-8
   PubMedGoogle Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar
• Sadok A, Marshall CJ. Rho GTPases: masters of cell migration. Small GTPases 2014;5:e29710. doi:10.4161/sgtp.29710
   PubMedGoogle Scholar
• Schoenwaelder SM, Burridge K. Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small GTPase Rho. A novel role for the calpain inhibitor calpeptin in the inhibition of protein-tyrosine phosphatases. J Biol Chem. 1999;274(20):14359–14367. 10.1074/jbc.274.20.14359
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5):52. doi:10.3390/cancers9050052
   PubMed Web of Science ®Google Scholar
• Tyagi G, Kapoor N, Chandra G, Gambhir L. Cure lies in nature: medicinal plants and endophytic fungi in curbing cancer. 3 Biotech. 2021;11(6):263. doi:10.1007/s13205-021-02803-x
   PubMedGoogle Scholar
• Susanti S, Iwasaki H, Itokazu Y, Nago M, Taira N, Saitoh S, Oku H. Tumor specific cytotoxicity of arctigenin isolated from herbal plant Arctium lappa L. J Nat Med. 2012;66(4):614–621. doi:10.1007/s11418-012-0628-0
   PubMed Web of Science ®Google Scholar
• Zhang M, Cai S, Zuo B, Gong W, Tang Z, Zhou D, Weng M, Qin Y, Wang S, Liu J, et al. Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway. Tumour Biol. 2017:39(5):1010428317698359. doi:10.1177/1010428317698359
   Google Scholar
• Huang Q, Qin S, Yuan X, Zhang L, Ji J, Liu X, Ma W, Zhang Y, Liu P, Sun Z, et al. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. Oncol Rep. 2017;38(1):598–606. doi:10.3892/or.2017.5667
   PubMed Web of Science ®Google Scholar
• Miyazaki J, Ito K, Fujita T, Matsuzaki Y, Asano T, Hayakawa M, Asano T, Kawakami Y. Progression of human renal cell carcinoma via inhibition of RhoA-ROCK axis by PARG1. Transl Oncol. 2017;10(2):142–152. doi:10.1016/j.tranon.2016.12.004
   PubMed Web of Science ®Google Scholar
• Ray RM, Patel A, Viar MJ, McCormack SA, Zheng Y, Tigyi G, Johnson LR. RhoA inactivation inhibits cell migration but does not mediate the effects of polyamine depletion. Gastroenterology. 2002;123(1):196–205. doi:10.1053/gast.2002.34216
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Genno S, Takeda T, Matsuda T, Kimura N, Yamashita Y, Morii Y, Shimomura K, Nishida S. Rhosin suppressed tumor cell metastasis through inhibition of Rho/YAP pathway and expression of RHAMM and CXCR4 in melanoma and breast cancer cells. Biomedicines. 2021;9(1):35. doi:10.3390/biomedicines9010035
   PubMed Web of Science ®Google Scholar
• Yan G, Zou R, Chen Z, Fan B, Wang Z, Wang Y, Yin X, Zhang D, Tong L, Yang F, et al. Silencing RhoA inhibits migration and invasion through Wnt/beta-catenin pathway and growth through cell cycle regulation in human tongue cancer. Acta Biochim Biophys Sin (Shanghai). 2014;46(8):682–690. doi:10.1093/abbs/gmu051
   PubMed Web of Science ®Google Scholar
• Hou T-C, Lin J-J, Wen H-C, Chen L-C, Hsu S-P, Lee W-S. Folic acid inhibits endothelial cell migration through inhibiting the RhoA activity mediated by activating the folic acid receptor/cSrc/p190RhoGAP-signaling pathway. Biochem Pharmacol. 2013;85(3):376–384. doi:10.1016/j.bcp.2012.11.011
   PubMed Web of Science ®Google Scholar
• Kakiashvili E, Dan Q, Vandermeer M, Zhang Y, Waheed F, Pham M, Szászi K. The epidermal growth factor receptor mediates tumor necrosis factor-alpha-induced activation of the ERK/GEF-H1/RhoA pathway in tubular epithelium. J Biol Chem. 2011;286(11):9268–9279. doi:10.1074/jbc.M110.179903
   PubMed Web of Science ®Google Scholar
• Cossu-Rocca P, Muroni MR, Sanges F, Sotgiu G, Asunis A, Tanca L, Onnis D, Pira G, Manca A, Dore S, et al. EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma. Am J Cancer Res. 2016;6:71–83.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Amato R, Todd M, Hwu WJP, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003;21(1):99–101. doi:10.1023/a:1022928612511
   PubMed Web of Science ®Google Scholar